Drug Trial Radar · NCT06880770
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
288
Planned (sponsor's estimate)
Start
Apr 24, 2025
Primary completion
Mar 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.
Conditions
- Severe Hypertriglyceridemia
Interventions
PlozasiranDrug
ARO-APOC3 injection
PlaceboDrug
sterile normal saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Positively Adjudicated AP Event (Event Occurring More Than 10 Days After First Dose of Study Drug)Time frame: Randomization up to end of Double Blind Treatment Period compared to placebo (Approximate Maximum 50 Months)]
Locations
140 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California · Recruiting
Clinical Research Site 4
Santa Clarita, California · Recruiting
Research Site
New Haven, Connecticut · Recruiting
Clinical Research Site 6
Springfield, Illinois · Recruiting
Research Site
Indianapolis, Indiana · Recruiting
Research Site
Kansas City, Kansas · Recruiting
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
St Louis, Missouri · Recruiting
Clinical Research Site 5
North Platte, Nebraska · Recruiting
Research Site
New York, New York · Recruiting
Clinical Research Site 3
Greensboro, North Carolina · Recruiting
Research Site
Wilmington, North Carolina · Recruiting
Clinical Research Site 7
Philadelphia, Pennsylvania · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Clinical Research Site 1
Mesquite, Texas · Recruiting
Clinical Research Site 2
San Antonio, Texas · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Research Site
Ramos Mejía, Buenos Aires, Argentina · Recruiting
Research Site
Córdoba, Córdoba Province, Argentina · Recruiting
Research Site
Córdoba, Córdoba Province, Argentina · Recruiting
Research Site
Rosario, Santa Fe Province, Argentina · Recruiting
Research Site
Graz, Austria · Recruiting
Research Site
Linz, Austria · Recruiting
Research Site
Vienna, Austria · Recruiting
Research Site
Brussels, Belgium · Recruiting
Research Site
Ghent, Belgium · Recruiting
Research Site
São Paulo, Brazil · Recruiting
Research Site
Fortaleza, Ceará, Brazil · Recruiting
Research Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Research Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Research Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Research Site
Curitiba, Paraná, Brazil · Recruiting
Research Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Research Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Research Site
Pôrto Alegre, Rio Grande do Sul, Brazil · Recruiting
Research Site
São Paulo, São Paulo, Brazil · Recruiting
Research Site
São Paulo, São Paulo, Brazil · Not yet recruiting
Research Site
Burgas, Bulgaria · Recruiting
Research Site
Dimitrovgrad, Bulgaria · Recruiting
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.